CN111973716A - Traditional Chinese medicine composition with effect of treating metabolic syndrome and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition with effect of treating metabolic syndrome and preparation method and application thereof Download PDFInfo
- Publication number
- CN111973716A CN111973716A CN202010923678.2A CN202010923678A CN111973716A CN 111973716 A CN111973716 A CN 111973716A CN 202010923678 A CN202010923678 A CN 202010923678A CN 111973716 A CN111973716 A CN 111973716A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- parts
- chinese medicine
- metabolic syndrome
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 164
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 68
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims abstract description 68
- 230000000694 effects Effects 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 240000008042 Zea mays Species 0.000 claims abstract description 13
- 241001522129 Pinellia Species 0.000 claims abstract description 12
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 claims abstract description 12
- 244000153955 Reynoutria sachalinensis Species 0.000 claims abstract description 12
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 11
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 11
- 235000005822 corn Nutrition 0.000 claims abstract description 11
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 claims abstract description 8
- 241000304195 Salvia miltiorrhiza Species 0.000 claims abstract 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 abstract description 12
- 230000036772 blood pressure Effects 0.000 abstract description 11
- 108010074051 C-Reactive Protein Proteins 0.000 abstract description 8
- 102100032752 C-reactive protein Human genes 0.000 abstract description 8
- 230000037396 body weight Effects 0.000 abstract description 7
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 6
- 230000000302 ischemic effect Effects 0.000 abstract description 6
- 230000004060 metabolic process Effects 0.000 abstract description 6
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 abstract description 5
- 229930186217 Glycolipid Natural products 0.000 abstract description 5
- 210000000653 nervous system Anatomy 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 description 74
- 210000004369 blood Anatomy 0.000 description 33
- 239000008280 blood Substances 0.000 description 33
- 230000002829 reductive effect Effects 0.000 description 28
- 206010062717 Increased upper airway secretion Diseases 0.000 description 24
- 241000700159 Rattus Species 0.000 description 24
- 208000026435 phlegm Diseases 0.000 description 24
- 230000008859 change Effects 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 12
- 150000003626 triacylglycerols Chemical class 0.000 description 10
- 230000003213 activating effect Effects 0.000 description 8
- 210000000232 gallbladder Anatomy 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 108010028554 LDL Cholesterol Proteins 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 230000003187 abdominal effect Effects 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000035488 systolic blood pressure Effects 0.000 description 6
- 108010049003 Fibrinogen Proteins 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 108010010234 HDL Lipoproteins Proteins 0.000 description 5
- 102000015779 HDL Lipoproteins Human genes 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229940012952 fibrinogen Drugs 0.000 description 5
- 244000132619 red sage Species 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 4
- 240000007164 Salvia officinalis Species 0.000 description 4
- 210000000941 bile Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003172 expectorant agent Substances 0.000 description 4
- 230000003419 expectorant effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 235000005412 red sage Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000008845 cholagoga Substances 0.000 description 3
- 229940124571 cholagogue Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 235000007244 Zea mays Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940089639 cornsilk Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 239000001231 zea mays silk Substances 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 206010042727 Swollen tongue Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010043946 Tongue conditions Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000003631 expected effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000018914 glucose metabolism disease Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition with a function of treating metabolic syndrome, which is prepared from the following traditional Chinese medicine raw materials in parts by weight: 20-30 parts of corn stigma, 10-15 parts of giant knotweed, 3-6 parts of prepared pinellia tuber, 6-9 parts of dried orange peel and 10-15 parts of salvia miltiorrhiza. The traditional Chinese medicine composition can reduce the body weight of a patient suffering from metabolic syndrome complicated with ischemic cerebrovascular disease, and reduce the waist circumference and body mass index; lowering blood pressure; improving glycolipid metabolism; reducing C-reactive protein; improving carotid plaque, pulse wave velocity and ankle-brachial index; improving the traditional Chinese medicine syndrome score, the nervous system score and the life quality score without obvious side effect. The invention also discloses a preparation method and application of the traditional Chinese medicine composition for treating metabolic syndrome.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition with a function of treating metabolic syndrome, and a preparation method and application thereof.
Background
Metabolic Syndrome (MS) is a group of clinical signs that are developed by aggregation such as obesity, hyperglycemia (diabetes or impaired glucose regulation), dyslipidemia [ hypertriglyceridemia (TG) and/or low-density lipoprotein cholesterol (LDL-c) emia ], hypertension and the like, and seriously affect the health of the body, and is a combination of risk factors that are related to each other metabolically. Specific causes for risk factors for metabolic syndrome have not been discovered, and it is now largely believed that insulin resistance, abdominal obesity, dyslipidemia, endothelial dysfunction, chronic low grade inflammation, and the like may be involved.
According to the characteristics of the metabolic syndrome, the traditional Chinese medicine can be classified into the categories of 'splenic fever', 'diabetes', 'vertigo', 'fat and fullness' and the like in the traditional Chinese medicine. The metabolic syndrome is a systemic and multisystem disease, involving viscera, qi and blood, body fluids, yin and yang, producing various pathological products such as heat, dampness, phlegm, stasis, etc., and the disease location is mainly in spleen, liver and kidney. The spleen governs transportation and transformation, the liver governs smoothing flow of qi, and the kidney governs water and stores innate essence, playing an extremely important role in the metabolism of human body substances. Dysfunction of the spleen, liver and kidney can be caused by the combined action of improper diet, movement due to long-term lying, and lassitude and constitutional factors. Failure of the spleen to transport, liver to disperse and purge, and kidney essence to evaporate can cause disorder of qi, blood and body fluids in the body, leading to qi stagnation, phlegm obstruction and blood stasis. Phlegm-dampness and blood stasis are both pathological products and can also become pathogenic factors, further affecting the normal operation of qi, blood and body fluids, and the phlegm-dampness and blood stasis blocks the meridians of the viscera, thus causing the deficiency of qi, blood, yin and yang of the viscera and finally causing the metabolic syndrome of mixed deficiency and excess.
At present, the clinical medicine scheme for treating metabolic syndrome lacks unified standards, often fails to achieve the expected effect, has certain side effects on human bodies, and has important significance in searching medicines with exact curative effect and few side effects.
Disclosure of Invention
The invention aims to provide the traditional Chinese medicine composition which is scientific and reasonable in proportion, can obviously improve the clinical symptoms of patients with metabolic syndrome and has no toxic or side effect, aiming at the defects in the prior art; the invention also aims to provide a preparation method and application of the traditional Chinese medicine composition.
In order to achieve the purpose, the invention adopts the technical scheme that:
the invention provides a traditional Chinese medicine composition with the effect of treating metabolic syndrome, which is prepared from the following traditional Chinese medicine raw materials in parts by weight: 20-30 parts of corn stigma, 10-15 parts of giant knotweed, 3-6 parts of prepared pinellia tuber, 6-9 parts of dried orange peel and 10-15 parts of salvia miltiorrhiza.
Further, the traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 25 parts of corn stigma, 12.5 parts of giant knotweed, 4.5 parts of prepared pinellia tuber, 7.5 parts of dried orange peel and 12.5 parts of salvia miltiorrhiza.
The second aspect of the invention provides a preparation method of a traditional Chinese medicine composition for treating metabolic syndrome, which comprises the following steps:
weighing the traditional Chinese medicine raw materials in corresponding parts by weight, putting the traditional Chinese medicine raw materials into a medicine pot, and adding water to soak for 10-30 minutes; decocting with strong fire for 10-25 min; turning to soft fire, and continuing decocting for 10-25 minutes; extinguishing fire, filtering to remove residue to obtain filtrate, and obtaining the traditional Chinese medicine composition.
Further, in the step one, the total weight ratio of the added water to the traditional Chinese medicine raw materials is 4:1-10: 1.
Further preferably, in the step one, the total weight ratio of the added water to the traditional Chinese medicine raw materials is 6:1-8: 1.
The third aspect of the invention provides application of the traditional Chinese medicine composition with the effect of treating metabolic syndrome in preparing a medicine for treating metabolic syndrome.
Further, the medicament for treating the metabolic syndrome also comprises a pharmaceutically acceptable carrier.
By adopting the technical scheme, compared with the prior art, the invention has the following technical effects:
based on the recognition that the disadvantage of shaoyang pivot machine is the origin of the onset of metabolic syndrome and phlegm stasis is the important pathological basis, the invention screens out natural medicines with the functions of benefiting gallbladder, reducing phlegm and activating blood through a large number of experiments, and obtains the traditional Chinese medicine composition for treating metabolic syndrome with obvious curative effect, low cost and small toxic and side effect according to a certain weight ratio.
The traditional Chinese medicine composition provided by the invention can reduce the body weight of a patient suffering from metabolic syndrome complicated with ischemic cerebrovascular disease, and reduce the waist circumference and body mass index; lowering blood pressure; improving glycolipid metabolism; reducing C-reactive protein; improving carotid plaque, pulse wave velocity and ankle-brachial index; improving the traditional Chinese medicine syndrome score, the nervous system score and the life quality score without obvious side effect.
The preparation method of the invention is simple and easy to implement, is easy to produce and prepare, and can extract the effective components of each medicine component to the maximum extent.
Detailed Description
The present invention is further illustrated by the following examples, which are not to be construed as limiting the invention.
Examples
Firstly, weighing the raw materials of the traditional Chinese medicine
25 parts of corn stigma, 12.5 parts of giant knotweed, 4.5 parts of prepared pinellia tuber, 7.5 parts of dried orange peel and 12.5 parts of salvia miltiorrhiza.
Second, analysis of prescription
According to the traditional Chinese medicine theory and the clinical manifestations of metabolic syndrome, the 'shaoyang pivot mechanism disadvantage' is the origin of the onset of the metabolic syndrome, phlegm stasis is the important pathological basis, and the prescription for promoting bile flow, eliminating phlegm and activating blood is adopted as the treatment method. Through a large number of experimental screens, the optimally obtained traditional Chinese medicine composition is prepared from corn stigma, giant knotweed rhizome, prepared pinellia tuber, dried orange peel and red sage root, and the above 5 traditional Chinese medicines are compatible, so that the traditional Chinese medicine composition has the effects of clearing heat, benefiting gallbladder, reducing phlegm and promoting blood circulation.
Corn silk: sweet and light taste, mild nature, entering liver, gallbladder and bladder meridians, and has the effects of clearing liver-fire, promoting bile flow, inducing diuresis and relieving swelling. Contains active ingredients such as flavonoids, polysaccharides, sterols, saponins, alkaloids, organic acids, alkanes, and amino acids. The effect of the corn stigma is reviewed in the early stage of the subject group and relevant articles are published: the corn stigma and the active ingredients thereof have wide pharmacological activity, have obvious effects of reducing body mass, reducing blood pressure, blood sugar and blood fat, have good prevention and treatment effects on metabolic syndrome component diseases, are widely applied to treatment of clinical metabolic syndrome, and have no obvious side effect.
Giant knotweed rhizome: slightly bitter in taste and slightly cold in nature, entering liver, gallbladder and lung meridians. Has effects of promoting diuresis, eliminating jaundice, clearing heat, removing toxic substance, removing blood stasis, relieving pain, relieving cough, and eliminating phlegm. Modern pharmacological research shows that the giant knotweed and the active ingredients thereof have the effects of reducing blood fat, resisting atherosclerosis, inhibiting platelet aggregation, resisting thrombus, reducing blood sugar and the like.
Pinellia ternate and dried orange peel: ban Xia, pungent, warm, toxic; entering spleen and stomach meridians; has the effects of eliminating dampness and phlegm, lowering adverse qi and preventing vomiting, and relieving distension and fullness and reducing stagnation. Dried orange peel, bitter and pungent in flavor, warm in nature; entering lung and spleen meridians; has the effects of regulating qi, strengthening spleen, eliminating dampness and phlegm. Pinellia ternate and dried orange peel are used as representative medicines for the phlegm reduction method and are mainly composed of cores of a large amount of phlegm reduction compounds, are usually used in a matching manner, have the effects of reducing phlegm and eliminating dampness, and are very wide in clinical application.
Red sage root: bitter and slightly cold in taste. It enters heart and liver meridians. Has the effects of activating blood circulation to dissipate blood stasis, stimulating the menstrual flow to relieve pain, clearing away the heart-fire and relieving restlessness, cooling blood and eliminating carbuncle. The salvia miltiorrhiza, which is a common traditional Chinese medicine for promoting blood circulation and removing blood stasis, has the functions of expanding blood vessels, reducing blood fat, blood pressure and blood sugar, and can improve microcirculation and reduce blood viscosity.
The prescription for promoting bile flow, eliminating phlegm and promoting blood circulation can reduce the weight of patients with metabolic syndrome complicated with ischemic cerebrovascular disease, and reduce waist circumference and body mass index; lowering blood pressure; improving glycolipid metabolism; reducing C-reactive protein; improving carotid plaque, pulse wave velocity and ankle-brachial index; improving the traditional Chinese medicine syndrome score, the nervous system score and the life quality score without obvious side effect. The prescription for benefiting gallbladder, reducing phlegm and activating blood circulation can obviously improve the component diseases of metabolic syndrome, relieve the symptoms and physical signs of metabolic syndrome combined with ischemic cerebrovascular disease, effectively prevent and treat the occurrence and development of ischemic cerebrovascular disease, improve the physical and mental health of patients and improve the life quality.
Third, preparation method
Weighing the traditional Chinese medicine raw materials in corresponding parts by weight, putting the traditional Chinese medicine raw materials into a medicine pot, and adding water to soak for 10-30 minutes; decocting with strong fire for 10-25 min; turning to soft fire, and continuing decocting for 10-25 minutes; extinguishing the fire, filtering and removing slag to obtain filtrate;
stirring to obtain the Chinese medicinal composition.
Mixing the above Chinese medicinal composition with pharmaceutically acceptable vehicle, and making into oral liquid, granule, capsule or tablet for treating metabolic syndrome.
The effective combination of the components mutually supports, has the effects of clearing heat, benefiting gallbladder, reducing phlegm and activating blood circulation, can be effectively used for dialectically treating metabolic syndrome, and is proved by experiments effectively and fully, and the related experimental data are as follows:
first, animal experiment
The experimental method comprises the following steps: selecting 24 SPF male SD rats with the age of 6-8 weeks, adaptively feeding the SPF male SD rats for one week, and then randomly dividing the SPF male SD rats into 2 groups, a blank group (n is 8) and a Model group (n is 16), wherein the rats in the Control group are fed with common feed, and the rats in the Model group are fed with high-fat high-sugar high-salt feed. Molding was continued for 12 weeks. After molding, the Model component is divided into a metabolic syndrome group (MS group, n is 8) and a formula for benefiting gallbladder, reducing phlegm and activating blood circulation (namely corn stigma, giant knotweed rhizome, prepared pinellia tuber, dried orange peel and salvia miltiorrhiza) (LHH group, n is 8). After 13 weeks, the Control group and the MS group are subjected to normal saline intragastric administration, the LHH group is subjected to intragastric administration of the traditional Chinese medicine liquid with the concentration of 5g/ml, and the MS group and the LHH group are fed with high-fat, high-sugar and high-salt feed; the intervention time of the traditional Chinese medicine is 6 weeks. At the end of week 18, the abdominal aorta was bled and serum Total Cholesterol (TC), Triglycerides (TG), low density lipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol (HDL-c), fasting plasma glucose (FBG), fasting plasma insulin (FINS) were examined and Insulin Resistance Index (IRI) was calculated.
1.1 Effect of cholagogic, expectorant, and blood-activating prescription on weight and abdominal circumference of MS rats
After 6 weeks of Chinese herbal intervention, the rats were measured for body weight and abdominal circumference. The results show that the weight and abdominal circumference of the MS group are obviously increased compared with the Control group (P < 0.05). In the LHH group, the body weight and abdominal circumference of the rats were reduced (P <0.05) compared with the MS group (see Table 1). The results show that LHH can effectively reduce the weight and abdominal circumference of the MS rats.
TABLE 1
Note: p <0.05 compared to Control group; Δ P <0.05 compared to MS group.
1.2 Effect of cholagogue, expectorant, blood circulation-promoting prescription on systolic pressure of MS rat
After 6 weeks of the herbal intervention, the systolic blood pressure of the rats was measured using a rat tail artery non-invasive sphygmomanometer and the LHH group was found to be significantly reduced (P <0.05) compared to the MS group (see table 2). LHH is shown to reduce blood pressure of MS rats.
TABLE 2
Note: p <0.05 compared to Control group; Δ P <0.05 compared to MS group.
1.3 Effect of cholagogue, expectorant, blood circulation-promoting formula on sugar metabolism of MS rats
The serum FBG and the FINS are obtained at the end of 18 weeks of the experiment, and the result shows that the serum FBG and the FINS of the rats in the LHH group are obviously reduced and have statistical difference (P is less than 0.05) compared with the MS group, the IRI is calculated, and the result shows that the IRI is also obviously reduced and has statistical difference (P is less than 0.05) (see table 3), which indicates that the LHH can treat the glucose metabolism disorder caused by the high-fat, high-sugar and high-salt diet of the rats.
TABLE 3
Note: p <0.05 compared to Control group; Δ P <0.05 compared to MS group.
1.4 Effect of cholagogue, expectorant, blood circulation-promoting formula on lipid metabolism of MS rats
Compared with the MS group, the serum TG, TC and LDL-c of the rats in the LHH group are remarkably reduced and are statistically different (P <0.05), and compared with the MS group, the HDL-c is remarkably increased (P <0.05) (Table 4), which indicates that the LHH can treat the lipid metabolism disorder caused by high-fat, high-sugar and high-salt diet of the rats.
TABLE 4
Note: p <0.05 compared to blank group; Δ P <0.05 compared to model group.
After the rats are fed by the high-fat, high-sugar and high-salt diet for 12 weeks, the body weight and the abdominal circumference of the rats are obviously increased, TC, LDL-c, FINS, IRI and FBG are obviously increased, and the blood pressure is obviously increased. The results show that: the high-fat, high-sugar and high-salt diet can induce rat obesity and glycolipid metabolic disorder, increase blood pressure and successfully model MS rats.
After 6 weeks of gastric lavage with LHH, TC, TG, LDL-c, FINS and IRI were significantly decreased and HDL-c was significantly increased as compared with the MS group, and the results showed that: LHH can obviously improve obesity and glycolipid metabolic disturbance of MS rats and reduce blood pressure.
Second, clinical data
(1) Western diagnosis of metabolic syndrome diagnosis criteria: according to the metabolic syndrome diagnosis standard (diabetes and diabetes medical science division) revised from the Chinese type 2 diabetes prevention and treatment guideline of 2013:
central obesity: waist circumference (Waist Circumferene, WC) (Chinese) is more than or equal to 90cm for male and more than or equal to 85cm for female;
② hyperglycemia: the fasting blood sugar is more than or equal to 6.1mmol/L or the blood sugar is more than or equal to 7.8mmol/L after 2h of sugar load and/or the patient is diagnosed with diabetes and treated.
③ hypertension: blood pressure of 130/85mmHg or more and/or those with hypertension confirmed and treated.
Fourthly, the fasting TG is more than or equal to 1.70 mmol/L.
Fifthly, fasting HDL-C is less than 1.04 mmol/L. Three or more of the above can be diagnosed.
(2) Traditional Chinese medicine diagnosis: refer to the guidelines of clinical research on new Chinese medicinal drugs from the Ministry of public health of the people's republic of China for hypertension, hyperlipidemia, and diabetes (the first edition of 5 months in 2002).
The main symptoms are: chest distress, abdominal distention, head and body heaviness, vertigo, obesity, vomiting phlegm, sialism, and numbness and heaviness of limbs.
The secondary symptoms are as follows: palpitation, insomnia, pale mouth, poor appetite, dark yellow urine, and constipation.
Tongue pulse: swollen tongue, yellow and greasy coating and wiry and slippery pulse.
Syndrome of phlegm-heat accumulation: principal symptoms 3 (essential tongue); or 2 items for main symptoms (essential tongue condition) and 2 items for secondary symptoms are added for diagnosis.
(3) Quantitative grading and scoring standard of traditional Chinese medicine symptoms: quantitative grading and curative effect evaluation are given according to the guiding principle of clinical research of traditional Chinese medicines (new medicines) in 2002 of Ministry of public health of the people's republic of China. 0 point is recorded for asymptomatic; the mild degree of the chief complaint is scored as 2 points, the moderate degree is scored as 4 points, and the severe degree is scored as 6 points; the mild degree of the secondary symptoms is scored as 1 point, the moderate degree is scored as 2 points, and the severe degree is scored as 3 points.
(4) And (3) inclusion standard:
the medicine composition meets the above Western medicine diagnosis standard, i.e. metabolic syndrome complicated with ischemic cerebrovascular disease.
② the patients who accord with the syndrome differentiation standard of the phlegm-heat excessive syndrome in traditional Chinese medicine are 18-70 years old, and are not limited by men and women.
And thirdly, signing an informed consent and voluntarily receiving the test.
2.1 treatment regimens
The research adopts a random and contrast method, the patients with metabolic syndrome are divided into a Chinese and western medicine combined group (western medicine treatment aiming at MS related components and prescription for promoting bile flow, reducing phlegm and activating blood (corn silk, giant knotweed rhizome, prepared pinellia tuber, dried orange peel and red sage root)) and a western medicine group (western medicine treatment aiming at MS related components) according to the ratio of 1:1, and the two groups are subjected to healthy living behavior intervention for 18 months.
Combined traditional and western medicine: the Western medicine treats the MS component diseases (patients with hypertension, hyperlipidemia and hyperglycemia respectively carry out conventional blood pressure reduction, lipid regulation and blood sugar control treatment according to symptoms), and simultaneously, prescription for benefiting gallbladder, reducing phlegm and activating blood (corn stigma, giant knotweed rhizome, prepared pinellia tuber, dried orange peel and red sage root) is given. One patch every day, about 400ml decoction is decocted in one decoction in hospital or decocted by patient, and the decoction is taken twice in the morning and evening, and the treatment course is 18 months.
Western medicine group: the treatment is carried out on the MS component diseases (combined Chinese and Western medicine). The patients in the two groups fill in a metabolic syndrome questionnaire and a Chinese medicine symptom grading quantization table, clinical symptoms and physical signs, laboratory examination and Chinese medicine syndrome change conditions in 6, 12 and 18 months before and after intervention are observed and recorded, and the difference of each time point before and after intervention and the difference between each group are compared.
2.2 results
2.2.1 post-treatment sugar metabolism Change
The Fasting Plasma Glucose (FPG) before treatment in the combined Western and Chinese medicine groups was not statistically different from that in the Western medicine group (p > 0.05). FPG was significantly reduced after 6 months of treatment in both the combined Western and Chinese and Western groups, with statistical differences (p < 0.01). The combined Western and Western groups were compared with no statistical difference (p > 0.05).
TABLE 5 FPG: (
mmol/L)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
The Fasting Insulin (FINS) before treatment in the combined Western and Western groups was not statistically different (p > 0.05). After 6 months of treatment, FINS decreased significantly in both groups, with statistical differences (p < 0.01). The combined Western and Western groups were compared with no statistical difference (p > 0.05).
TABLE 6 FINS: (
mU/ml)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
The insulin sensitivity index (IRI) before treatment was not statistically different between the Western and Combined groups (p > 0.05). After 6 months of treatment in the combined traditional Chinese and western medicine group, the IRI is remarkably reduced, and the statistical difference is realized (p is less than 0.01). After 12 months of treatment in the western medicine group, the IRI is significantly reduced, and the difference is statistical (p < 0.01). The combined Western and Western groups were compared with no statistical difference (p > 0.05).
TABLE 7 IRI
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
2.2.2 post-treatment lipid metabolism changes
Change in Triglyceride (TG): there was no statistical difference in TG between the combined western and western groups before treatment (p > 0.05). TG was significantly reduced after 6 months of treatment in both groups with statistical differences (p < 0.01). The combined Western and Western groups were compared with no statistical difference (p > 0.05).
TABLE 8 TG (
mmol/L)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
High Density Lipoprotein (HDL) changes: the HDL before treatment was not statistically different between the Western and Chinese combination groups (p > 0.05). After 18 months of treatment, HDL was significantly elevated in both groups with statistical differences (p < 0.01). Compared with the Western medicine group, the Chinese and Western medicine combined group has no statistical difference (p > 0.05).
TABLE 9 HDL: (
mmol/L)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
2.2.3 weight Change after treatment
The weights before treatment were not statistically different between the western and western medicine combined group (p > 0.05). Body weight was significantly reduced at 6, 12 and 18 months after treatment in both groups with statistical differences (p < 0.01). The difference between the two groups was not statistically significant (p > 0.05).
TABLE 10 body weights: (
kg)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
2.2.4 post-treatment Body Mass Index (BMI) Change
The combined western and western groups had no statistical difference in pre-treatment Body Mass Index (BMI) (p > 0.05). BMI was significantly reduced with statistical differences (p <0.05, p <0.01) at 6, 12 and 18 months after treatment in both groups. Compared with the Western medicine group, the Chinese and Western medicine combined group has no statistical difference (p > 0.05).
TABLE 11 BMI
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
2.2.5 waistline Change after treatment
The waist circumference before treatment of the Chinese and Western medicine combination group and the Western medicine group is not statistically different (p > 0.05). Waistline of the two groups is reduced after 6 months of treatment, and statistical differences exist (p is less than 0.05, p is less than 0.01, and waistline change of a Chinese and western medicine combination group is more obvious (p is less than 0.05) compared with a western medicine group after 18 months of treatment.
TABLE 12 waist circumference (
cm)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
2.2.6 post-treatment systolic blood pressure changes
The systolic blood pressure before treatment was not statistically different between the combined Western and Western groups (p > 0.05). The systolic blood pressure was significantly reduced after 6 months of treatment in both groups compared to before treatment, with statistical differences (p < 0.01). Compared with the Western medicine group, the Chinese and Western medicine combined group has no statistical difference (p > 0.05).
TABLE 13 systolic blood pressure: (
mmHg)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
2.2.7 changes in Whole blood viscosity, plasma viscosity, hematocrit, Fibrinogen (FIB) after treatment
The whole blood viscosity, plasma viscosity, red blood cell pressure and FIB were not statistically different before treatment in the combined Western and Western groups (p > 0.05). After the treatment of the combination of traditional Chinese medicine and western medicine and the treatment of the western medicine, the changes of whole blood viscosity, plasma viscosity, hematocrit and FIB are not significant (p is more than 0.05). The two groups were compared without statistical difference (p > 0.05).
TABLE 14 Whole blood viscosity 200s-1
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
TABLE 15 Whole blood viscosity 1s-1
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
TABLE 16 plasma viscosity: (
mPas)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
TABLE 17 hematocrit: (
L/L)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
TABLE 18 FIB: (
g/L)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05, ^ p <0.01 with the Western medicine group
2.2.8 post-treatment C-reactive protein (CRP) changes
The CRP was not statistically different before treatment in the combined Western and Western groups (p > 0.05). CRP is obviously reduced after 6 months, 12 months and 18 months of treatment in the combined traditional Chinese and western medicine group and the western medicine group, and statistical differences exist (p is less than 0.05, and p is less than 0.01). Compared with the Western medicine group, the Chinese and Western medicine combined group has no statistical difference (p > 0.05).
TABLE 19 CRP: (
mg/L)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05, ^ p <0.01 with the Western medicine group
2.2.9 carotid plaque condition change after treatment
TABLE 20 mean change in carotid plaque number: (
One)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
The mean number of carotid plaques before treatment was not statistically different between the combined western and western groups (p > 0.05). After the combined traditional Chinese and western medicine treatment group is used for 18 months, the number of carotid plaque is remarkably reduced, and the statistical difference is achieved (p is less than 0.05); after treatment, the number of carotid plaque in the combined traditional Chinese and western medicine group is significantly reduced and has statistical difference (p <0.05) compared with the western medicine group.
TABLE 21 maximum carotid plaque Length variation ((C))
mm)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
There was no statistical difference in the maximum length of carotid plaque before treatment in the combined western and western groups (p > 0.05). After 12 months of treatment in the combined traditional Chinese and western medicine group, the maximum length of carotid plaque is obviously reduced, and statistical difference exists (p is less than 0.01); compared with the western medicine group, the maximum length of carotid plaque in the combined traditional Chinese and western medicine group is obviously reduced, and the statistical difference is realized (p < 0.05).
TABLE 22 maximum thickness variation of carotid plaque: (
mm)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
The maximum thickness of the carotid plaque before treatment was not statistically different between the western and Chinese combination groups and the western group (p > 0.05). After 12 months of treatment in the combined traditional Chinese and western medicine group, the maximum thickness of carotid plaque is obviously reduced, and statistical difference exists (p is less than 0.05); after treatment, the maximum carotid plaque thickness was significantly reduced in the combined western and chinese groups compared to the western group with statistical differences (p < 0.05).
TABLE 23 Crouse integral Change of carotid plaque
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
There was no statistical difference in the Crouse score before treatment in the combined western and western groups (p > 0.05). After the combined Chinese and Western treatment group is treated for 18 months, the Crouse integral of carotid plaque is obviously reduced, and the statistical difference is realized (p is less than 0.05); after treatment, the carotid plaque Crouse score of the combined traditional and western medicine group was significantly reduced with statistical differences (p <0.05) compared to the western medicine group.
2.2.10 post-treatment pulse wave (baPWV) Change
The combined Western and Western groups had no statistical difference in baPWV before treatment (p > 0.05). After 12 months of treatment in the combined traditional Chinese and western medicine group and the western medicine group, the baPWV is remarkably reduced, and the statistical difference is generated (p is less than 0.01). The treatment period is 18 months, compared with the western medicine group, the Chinese and western medicine combination group is obviously reduced, and the statistical difference is realized (p is less than 0.05).
TABLE 24 ba-PWV (b)
cm/s)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
2.2.11 ankle arm index (ABI) Change after treatment
TABLE 25 ABI changes
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
The ABI before treatment was not statistically different between the Western and Combined groups (p > 0.05). After 12 months of treatment in the combined traditional Chinese and western medicine group, ABI is remarkably increased, and statistical difference exists (p is less than 0.05); after 18 months of treatment, the ABI of the combined traditional Chinese and western medicine group is remarkably increased and has statistical difference (p < 0.05).
2.2.12 integral change of Chinese medicinal syndrome after treatment
The traditional Chinese medicine syndrome integration before treatment of the traditional Chinese medicine and western medicine combined group and the western medicine group have no statistical difference (p is more than 0.05). After the combination of the traditional Chinese medicine and the western medicine are treated for 6 months, the traditional Chinese medicine syndrome integral is obviously reduced, and statistical differences exist (p is less than 0.05, and p is less than 0.01). Compared with the western medicine group, after 12 months and 18 months of treatment, the traditional Chinese medicine syndrome integral of the combination of the traditional Chinese medicine and the western medicine is obviously reduced (p is less than 0.05, and p is less than 0.01).
TABLE 26 integral comparison of syndromes in TCM
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
2.2.13 post-treatment NIHSS score changes
TABLE 27 NIHSS score changes
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
The combination of western and chinese medicine and the western medicine group had no statistical difference in the pre-treatment NIHSS scores (p > 0.05). After the combined Chinese and western medicine treatment for 6 months, the NIHSS is remarkably reduced, and statistical differences exist (p is less than 0.05, and p is less than 0.01); the NIHSS is remarkably reduced after the western medicine group is treated for 6 months, and statistical differences exist (p is less than 0.05, and p is less than 0.01). The combination of Western and Western medicine groups showed no statistical difference (p >0.05) compared to the Western medicine group.
2.2.13 post-treatment BI score Change
TABLE 28 BI score Change
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
There was no statistical difference in pre-treatment BI scores between the combined western and western groups (p > 0.05). After 6 months of treatment in the combined traditional Chinese and western medicine group, the BI score is obviously increased, and the statistical difference exists (p is less than 0.05, and p is less than 0.01); the BI scores were significantly increased after 6 months of treatment in the Western group, with statistical differences (p <0.05, p < 0.01). Compared with the Western medicine group, after 18 months, the BI score of the Chinese and Western medicine combination group is obviously increased, and the statistical difference is realized (p < 0.05).
2.2.14 Change in Life Mass score after treatment
TABLE 29 body health score (PCS)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
There was no statistical difference in PCS score before treatment in both the western and chinese combination groups (p > 0.05). After the combined traditional Chinese and western medicine group is treated for 6 months, the PCS score is obviously increased, and the statistical difference exists (p is less than 0.05, and p is less than 0.01); PCS score was significantly increased after 12 months of treatment in the western group (p <0.05, p < 0.01). Compared with the western medicine group, after 18 months, the PCS score of the Chinese and western medicine combination group is obviously increased, and the statistical difference is realized (p is less than 0.05).
TABLE 30 mental health score (MCS)
Note: p <0.05, p <0.01 compared to month 0; comparing ^ p <0.05 and ^ p <0.01 with the Western medicine group.
The combined western and western groups had no statistical difference in pre-treatment MCS scores (p > 0.05). After the combined Chinese and Western medicine group is treated for 6 months, the MCS score is obviously increased, and the statistic difference exists (p is less than 0.05, and p is less than 0.01); the MCS score was significantly increased after 12 months of treatment in the western medicine group (p <0.05, p < 0.01). Compared with the western medicine group, the MCS score of the Chinese and western medicine combination group is obviously increased after 18 months, and the statistical difference is realized (p is less than 0.05).
While the invention has been described with reference to a preferred embodiment, it will be understood by those skilled in the art that various changes in form and detail may be made therein without departing from the spirit and scope of the invention.
Claims (7)
1. The traditional Chinese medicine composition with the effect of treating metabolic syndrome is characterized by being prepared from the following traditional Chinese medicine raw materials in parts by weight: 20-30 parts of corn stigma, 10-15 parts of giant knotweed, 3-6 parts of prepared pinellia tuber, 6-9 parts of dried orange peel and 10-15 parts of salvia miltiorrhiza.
2. The traditional Chinese medicine composition with the effect of treating metabolic syndrome according to claim 1, which is prepared from the following traditional Chinese medicine raw materials in parts by weight: 25 parts of corn stigma, 12.5 parts of giant knotweed, 4.5 parts of prepared pinellia tuber, 7.5 parts of dried orange peel and 12.5 parts of salvia miltiorrhiza.
3. The preparation method of the traditional Chinese medicine composition with the effect of treating metabolic syndrome according to any one of claims 1-2, characterized by comprising the following steps:
weighing the traditional Chinese medicine raw materials in corresponding parts by weight, putting the traditional Chinese medicine raw materials into a medicine pot, and adding water to soak for 10-30 minutes; decocting with strong fire for 10-25 min; turning to soft fire, and continuing decocting for 10-25 minutes; extinguishing fire, filtering to remove residue to obtain filtrate, and obtaining the traditional Chinese medicine composition.
4. The preparation method according to claim 3, wherein in the first step, the ratio of the added water to the total weight of the Chinese medicinal materials is 4:1-10: 1.
5. The preparation method according to claim 4, wherein in the first step, the ratio of the added water to the total weight of the Chinese medicinal materials is 6:1-8: 1.
6. Use of the Chinese medicinal composition for treating metabolic syndrome according to any one of claims 1 to 2 in the preparation of a medicament for treating metabolic syndrome.
7. The use of claim 6, wherein the medicament for treating metabolic syndrome further comprises a pharmaceutically acceptable carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010923678.2A CN111973716A (en) | 2020-09-04 | 2020-09-04 | Traditional Chinese medicine composition with effect of treating metabolic syndrome and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010923678.2A CN111973716A (en) | 2020-09-04 | 2020-09-04 | Traditional Chinese medicine composition with effect of treating metabolic syndrome and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111973716A true CN111973716A (en) | 2020-11-24 |
Family
ID=73446967
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010923678.2A Pending CN111973716A (en) | 2020-09-04 | 2020-09-04 | Traditional Chinese medicine composition with effect of treating metabolic syndrome and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111973716A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1541671A (en) * | 2003-04-30 | 2004-11-03 | 无锡山禾药业股份有限公司 | Medicine for treating angina pectoris and its preparation and application |
| US20090148536A1 (en) * | 2005-07-18 | 2009-06-11 | Laiwang Guo | Traditional chinese medicine composition to treat rheumatoid arthritis and Preparation method thereof |
| CN105749239A (en) * | 2016-04-25 | 2016-07-13 | 徐慧灵 | Traditional Chinese medicine decoction for treating hyperlipidemia |
| CN108743848A (en) * | 2018-08-29 | 2018-11-06 | 侯兰兰 | A kind of Chinese medicine preparation and preparation method thereof for treating hyperlipidemia |
-
2020
- 2020-09-04 CN CN202010923678.2A patent/CN111973716A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1541671A (en) * | 2003-04-30 | 2004-11-03 | 无锡山禾药业股份有限公司 | Medicine for treating angina pectoris and its preparation and application |
| US20090148536A1 (en) * | 2005-07-18 | 2009-06-11 | Laiwang Guo | Traditional chinese medicine composition to treat rheumatoid arthritis and Preparation method thereof |
| CN105749239A (en) * | 2016-04-25 | 2016-07-13 | 徐慧灵 | Traditional Chinese medicine decoction for treating hyperlipidemia |
| CN108743848A (en) * | 2018-08-29 | 2018-11-06 | 侯兰兰 | A kind of Chinese medicine preparation and preparation method thereof for treating hyperlipidemia |
Non-Patent Citations (1)
| Title |
|---|
| 王兵: "中医药防治代谢综合征，预防系脑血管病", 《HTTPS://WWW.HAODF.COM/ZHUANJIAGUANDIAN/ EWANGBING_6076520515.HTM》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100473404C (en) | Hypertension treating Chinese medicine preparation | |
| CN105749179A (en) | Traditional Chinese medicine composition for treating metabolic syndrome | |
| JP6145552B1 (en) | Fatty liver treatment composition | |
| CN102580048A (en) | Chinese medicine for losing weight and preparation method thereof | |
| CN109820943B (en) | Zhuang medicine preparation for treating gout and preparation method thereof | |
| CN104147536A (en) | Medicine composition for treating haemorrhoids and preparation method thereof | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN107281386B (en) | Method for preparing medicine for treating hypertension by using dendrobium officinale and radish seeds and application | |
| CN101530565A (en) | Chinese traditional medicine preparation used for curing diabetes and preparation method thereof | |
| CN111973716A (en) | Traditional Chinese medicine composition with effect of treating metabolic syndrome and preparation method and application thereof | |
| CN103525640B (en) | Energy-keeping yang-tonifying wine | |
| CN105194355A (en) | Traditional Chinese medicine preparation for treating primary hypertension | |
| CN104984097A (en) | Chinese herba preparation for treating primary hypertension and application thereof | |
| CN104587304A (en) | Medicine for treating simple obesity and application of medicine | |
| CN104491718A (en) | Medicine for treating liver-depression and phlegm-stasis type mammary gland hyperplasia and preparation method | |
| CN116440224B (en) | Traditional Chinese medicine composition, preparation and preparation method | |
| CN117018105B (en) | Traditional Chinese medicine composition for treating impaired glucose tolerance and preparation method thereof | |
| CN116650599B (en) | Traditional Chinese medicine composition for resolving dampness and relieving arthralgia | |
| CN110693936B (en) | Traditional Chinese medicine composition for reducing uric acid and preventing and treating hyperuricemia or gout and application thereof | |
| CN115607634B (en) | Traditional Chinese medicine composition for preventing and treating hyperuricemia and gout and application thereof | |
| CN108403803B (en) | Chinese medicinal compound preparation for preventing and treating cardiovascular complications of diabetes | |
| CN101757527A (en) | Traditional Chinese medicine composition for treating nephritis and preparation method thereof | |
| CN105597020A (en) | Pharmaceutical composition for treating polycystic ovarian syndrome combined with mammary gland hyperplasia | |
| CN105126065A (en) | Traditional Chinese medicine composition for treating hyperlipidemia and purpose thereof | |
| CN118045141A (en) | A Chinese medicinal composition for treating diabetes, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201124 |
|
| RJ01 | Rejection of invention patent application after publication |